Stay updated on Canakinumab & Pembrolizumab Combo in Early NSCLC Clinical Trial
Sign up to get notified when there's something new on the Canakinumab & Pembrolizumab Combo in Early NSCLC Clinical Trial page.

Latest updates to the Canakinumab & Pembrolizumab Combo in Early NSCLC Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedA new revision entry, Revision v3.3.4, appears in the history. Revision v3.3.3 is removed from the list.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check30 days agoChange DetectedA new Revision: v3.3.3 has been added, and the HHS Vulnerability Disclosure link along with Revision: v3.3.2 has been removed.SummaryDifference0.1%

- Check58 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2 on the page header. This is a system update and does not modify any study data, eligibility, or user actions.SummaryDifference0.1%

- Check65 days agoChange DetectedRemoved the government funding status notice from the page; the trial record details and navigation remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check80 days agoChange DetectedThe screenshots show a minor UI/layout adjustment to the Version History list on the Record History page, with formatting changes but the same version data and fields. No core content or statuses were altered. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check109 days agoChange DetectedMajor update: announces a version upgrade to v3.2.0 and publicly states funding-related operational notices, including that transactions may not be processed until appropriations are enacted.SummaryDifference10%

Stay in the know with updates to Canakinumab & Pembrolizumab Combo in Early NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Canakinumab & Pembrolizumab Combo in Early NSCLC Clinical Trial page.